Democrats' policy package to include prescription drug cost controls and
Obamacare fix
Send a link to a friend
[July 20, 2022]
By Richard Cowan
WASHINGTON (Reuters) -U.S. Senate Majority
Leader Chuck Schumer said on Tuesday that prescription drug cost
controls and an Obamacare fix are the components Democrats will seek for
now in a fast-track domestic policy bill.
"The two things we want to do in reconciliation, that we're going to do
in reconciliation, are prescription drugs and a two-year extension of
ACA," Schumer told reporters.
"ACA" refers to the Affordable Care Act, commonly known as Obamacare.
Democrats are seeking to keep in place increased financial assistance
for people who qualify for subsidized health insurance under ACA. The
premium relief was offered as part of the American Rescue Plan enacted
in 2021, but is set to expire this year, which would result in stark
premium increases for millions of people unless Congress acts.
The prescription drug plan would allow Medicare, the government's health
plan for senior citizens and the disabled, to negotiate lower prices.
[to top of second column]
|
U.S. Senate Majority Leader Chuck Schumer (D-NY) speaks to reporters
following the Senate Democrats weekly policy lunch at the U.S.
Capitol in Washington, U.S., June 22, 2022. REUTERS/Elizabeth
Frantz/File Photo
"Reconciliation" refers to an
exclusive number of bills that can move through the Senate with a
simple majority of support in the 100-member chamber, instead of the
60 votes usually needed.
So far, Schumer has failed to win the backing of
Democratic Senator Joe Manchin for a major climate change initiative
and tax increases on some corporations as part of such legislation.
Without every one of his 50 Democratic caucus members, Schumer does
not have the votes to pass bills given solid Republican opposition.
(Reporting by Richard Cowan and Katharine Jackson; Editing by Leslie
Adler and Jonathan Oatis)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |